51842-68-3 Usage
Class
Quinoline carboxylic acids This indicates the chemical class to which the compound belongs, which is characterized by a quinoline ring and a carboxylic acid group.
Structure
Quinoline ring with a carboxylic acid and an ethoxy-phenyl group attached This describes the arrangement of atoms in the molecule, which is characterized by a quinoline ring with a carboxylic acid group and an ethoxy-phenyl group attached to it.
Biological activities
Antibacterial, antifungal, and antiviral These are some of the reported biological activities of 2-(4-ethoxy-phenyl)-quinoline-4-carboxylic acid, indicating its potential as a bioactive molecule.
Therapeutic applications
Potential treatment of various diseases This indicates that the compound has been studied for its potential use in the treatment of diseases.
Industrial applications
Building block in the synthesis of other organic compounds, used in pharmaceutical and agrochemical industries This indicates that 2-(4-ethoxy-phenyl)-quinoline-4-carboxylic acid may have practical applications in the synthesis of other compounds and in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 51842-68-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,1,8,4 and 2 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 51842-68:
(7*5)+(6*1)+(5*8)+(4*4)+(3*2)+(2*6)+(1*8)=123
123 % 10 = 3
So 51842-68-3 is a valid CAS Registry Number.
51842-68-3Relevant articles and documents
Identification of a β1/β2-Specific Sulfonamide Proteasome Ligand by Crystallographic Screening
Beck, Philipp,Reboud-Ravaux, Michèle,Groll, Michael
supporting information, p. 11275 - 11278 (2016/07/06)
The proteasome represents a validated drug target for the treatment of cancer, however, new types of inhibitors are required to tackle the development of resistant tumors. Current fluorescence-based screening methods suffer from low sensitivity and are limited to the detection of ligands with conventional binding profiles. In response to these drawbacks, a crystallographic screening procedure for the discovery of agents with a novel mode of action was utilized. The optimized workflow was applied to the screening of a focused set of compounds, resulting in the discovery of a β1/β2-specific sulfonamide derivative that noncovalently binds between subunits β1 and β2. The binding pocket displays significant differences in size and polarity between the immuno- and constitutive proteasome. The identified ligand thus provides valuable insights for the future structure-based design of subtype-specific proteasome inhibitors.
